Welcome to our dedicated page for BIOMARIN PHARMACEUTICAL SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
BioMarin Pharmaceutical reports 2025 total revenues of $3.2 billion, driven largely by growth in VOXZOGO and its enzyme therapy franchise. VOXZOGO generated $926.9 million in 2025 net product revenue, while enzyme therapies and other rare-disease drugs added diversified sales.
The company agreed in December 2025 to acquire Amicus Therapeutics for $4.8 billion in cash, funded by cash on hand, $850.0 million of 5.5% senior notes due 2034, and an expected $2.8 billion term loan plus a $600.0 million revolving credit facility. BioMarin plans to expand its portfolio with Fabry and late‑onset Pompe disease therapies.
BioMarin is exiting ROCTAVIAN after lower‑than‑anticipated commercial opportunities, recording about $240.0 million in 2025 restructuring charges for inventory write‑offs, asset impairments, and severance. As of February 19, 2026, it had 192,323,359 shares of common stock outstanding and continues advancing a robust pipeline, including BMN 333, BMN 351, and BMN 401.
BioMarin Pharmaceutical (BMRN) filed a Form 144 reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The notice lists multiple lots tied to prior acquisitions, including 1,474 shares from a stock option exercise (02/24/2023), 317 shares from an ESPP purchase (04/30/2023), 301 shares from an ESPP purchase (04/30/2024), and 23,969 shares from restricted stock vesting (03/15/2025).
BioMarin Pharmaceutical reported strong growth for 2025 and set higher profit goals for 2026 while reshaping its portfolio. Total revenues rose 13% to $3.221 billion, with fourth quarter revenues up 17% to $875 million. Growth was led by VOXZOGO, which delivered 26% full‑year revenue growth to $927 million, and Enzyme Therapies, up 9% to $2.105 billion.
Full‑year GAAP net income was $348.9 million and Non‑GAAP Income was $614 million, equal to Non‑GAAP diluted EPS of $3.15. Fourth quarter GAAP results showed a $47 million net loss due to approximately $240 million of charges tied to voluntarily withdrawing ROCTAVIAN from the market. Non‑GAAP income for the quarter was $89 million.
BioMarin announced a definitive agreement to acquire Amicus Therapeutics, adding Galafold and Pombiliti + Opfolda, and has secured about $3.7 billion of non‑convertible debt financing. For 2026, excluding any post‑close Amicus contribution, the company guides to total revenues of $3.325–$3.425 billion and Non‑GAAP diluted EPS of $4.95–$5.15, with an expected Non‑GAAP operating margin of about 40%.
BioMarin Pharmaceutical Inc. has closed a private offering of $850 million in 5.500% senior unsecured notes due 2034. The issue price was 100.000%, and the notes were sold to qualified institutional buyers and certain non-U.S. investors.
BioMarin plans to use the net proceeds, together with a new $2 billion senior secured term loan B facility, a $800 million term loan A facility and cash on hand, to fund the pending acquisition of Amicus Therapeutics, Inc. and related fees and expenses. It also expects to enter into a $600 million senior secured revolving credit facility and may borrow up to $150 million under it for transaction costs.
Offering proceeds are held in escrow until the Amicus acquisition closes. If the deal is not completed on or before December 19, 2026, or certain other events occur, BioMarin must redeem the notes at 100% of the initial issue price plus accrued interest. The notes are guaranteed by certain subsidiaries and are subject to covenants limiting additional debt, dividends, liens, asset sales and mergers.
BioMarin Pharmaceutical Inc. is raising debt financing to help fund its pending acquisition of Amicus Therapeutics. The company agreed to sell $850 million of 5.500% senior unsecured notes due 2034 in a private offering to qualified institutional buyers and non‑U.S. persons.
BioMarin also completed syndication of a new $2 billion senior secured term loan B facility, in addition to a previously arranged $800 million senior secured term loan A facility, and expects to enter into a $600 million senior secured revolving credit facility. It plans to use net proceeds from the notes, together with borrowings under the term facilities and cash on hand, to pay the Acquisition consideration and related fees and expenses. If the Acquisition is not completed by December 19, 2026, BioMarin must redeem the notes at 100% of their initial issue price plus accrued interest.
BioMarin Pharmaceutical Inc. estimates that it generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including about $920 million from sales of VOXZOGO®. As of December 31, 2025, it reports approximately $2.1 billion in cash, cash equivalents and investments, all on a preliminary, unaudited basis.
The company also announces plans to offer $850 million of senior unsecured notes due 2034 in a private placement and to arrange a $2 billion Term Loan B facility, a $800 million Term Loan A facility, and a $600 million new revolving credit facility. Together with potential borrowings of up to $150 million under the revolver, these financings are intended to fund the pending acquisition of Amicus Therapeutics, Inc. and related costs. BioMarin is providing supplemental risk factors and unaudited pro forma combined financial information to illustrate the impact of the acquisition and financing.
BioMarin Pharmaceutical’s VP and Chief Accounting Officer, Rashmi Virendra Ramchandani, reported new equity awards. On January 20, 2026, she received 18,540 shares of common stock and a separate grant of 7,070 shares, both at a stated price of $0, which the footnotes describe as restricted stock units granted on that date. After these awards, she directly beneficially owned 25,610 common shares.
She was also granted a stock option covering 18,220 shares of common stock at an exercise price of $56.31 per share. The option becomes exercisable as to 12/48 of the grant on January 20, 2027, with the remaining 1/48 vesting on the 20th day of each month thereafter, and it expires on January 19, 2036. These transactions reflect equity compensation rather than open‑market buying or selling.
BioMarin Pharmaceutical Inc. insider filing shows no holdings for a new officer. VP and Chief Accounting Officer Rashmi Virendra Ramchandani filed an initial ownership report on Form 3 for BioMarin Pharmaceutical Inc. The filing states that no securities of BioMarin are beneficially owned. This means that, as of the event date shown in the filing, the reporting officer does not report owning any shares or derivative securities of the company.
BioMarin Pharmaceutical Inc. reports that BlackRock, Inc. beneficially owns 17,560,751 shares of its common stock, representing 9.1% of the class as of December 31, 2025. BlackRock has sole voting power over 16,727,815 shares and sole dispositive power over 17,560,751 shares, with no shared voting or dispositive authority.
The shares are held across various clients and funds, and no single underlying person has more than five percent of BioMarin’s outstanding common stock. BlackRock states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioMarin.
BioMarin Pharmaceutical Inc. provided a preliminary financial update alongside its presentation at the J.P. Morgan Healthcare Conference. Based on unaudited results, the company estimates it generated approximately $3.2 billion in total revenues for the year ended December 31, 2025, including about $920 million from VOXZOGO® sales for the same period. BioMarin also expects an asset write-down related to ROCTAVIAN in the fourth quarter of 2025 of approximately $230 million to $260 million.
Of this write-down, around $120 million to $125 million, or roughly $(0.60) to $(0.64) per diluted share assuming about 200 million weighted-average diluted shares outstanding, is expected to reduce the company’s Non-GAAP Income and Non-GAAP Diluted EPS for 2025. Excluding the impact of this asset write-down, BioMarin states that its previously issued full-year 2025 Non-GAAP Diluted EPS guidance remains unchanged. All figures are preliminary, unaudited, and subject to normal year-end closing procedures.